- Home
- ILMN vs FFIV Comparison
ILMN vs FFIV Comparison
Compare ILMN & FFIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILMN
- FFIV
- Stock Information
- Founded
- ILMN 1998
- FFIV 1996
- Country
- ILMN United States
- FFIV United States
- Employees
- ILMN N/A
- FFIV N/A
- Industry
- ILMN Medical Specialities
- FFIV Computer Communications Equipment
- Sector
- ILMN Health Care
- FFIV Telecommunications
- Exchange
- ILMN Nasdaq
- FFIV Nasdaq
- Market Cap
- ILMN 15.3B
- FFIV 18.0B
- IPO Year
- ILMN 2000
- FFIV 1999
- Fundamental
- Price
- ILMN $96.70
- FFIV $341.81
- Analyst Decision
- ILMN Buy
- FFIV Hold
- Analyst Count
- ILMN 15
- FFIV 11
- Target Price
- ILMN $124.27
- FFIV $314.90
- AVG Volume (30 Days)
- ILMN 1.7M
- FFIV 451.6K
- Earning Date
- ILMN 11-03-2025
- FFIV 10-27-2025
- Dividend Yield
- ILMN N/A
- FFIV N/A
- EPS Growth
- ILMN N/A
- FFIV 22.06
- EPS
- ILMN 7.91
- FFIV 11.34
- Revenue
- ILMN $4,284,000,000.00
- FFIV $3,024,656,000.00
- Revenue This Year
- ILMN N/A
- FFIV $11.86
- Revenue Next Year
- ILMN $2.74
- FFIV $4.03
- P/E Ratio
- ILMN $12.21
- FFIV $30.18
- Revenue Growth
- ILMN N/A
- FFIV 8.94
- 52 Week Low
- ILMN $68.70
- FFIV $213.24
- 52 Week High
- ILMN $156.66
- FFIV $343.84
- Technical
- Relative Strength Index (RSI)
- ILMN 47.19
- FFIV 66.93
- Support Level
- ILMN $95.77
- FFIV $325.85
- Resistance Level
- ILMN $103.00
- FFIV $343.84
- Average True Range (ATR)
- ILMN 3.53
- FFIV 6.81
- MACD
- ILMN 0.02
- FFIV 1.14
- Stochastic Oscillator
- ILMN 48.30
- FFIV 87.91
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
About FFIV F5 Inc.
F5 is a market leader in the application delivery controller market. The company sells products for security, application performance, and automation. Its three customer verticals are enterprises, service providers, and government entities. Revenue is evenly split between its services business and products business with revenue trending toward products due to software adoption. The Seattle-based firm was incorporated in 1996, and went public in 1999.